In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GENESIS Pharma S.A.

https://www.genesispharma.com

Latest From GENESIS Pharma S.A.

Henlius Gets Australian Nod For Trastuzumab

Shanghai Henlius Biotech has celebrated an Australian approval for its Hanquyou trastuzumab biosimilar rival to Herceptin, which has been approved by the country’s TGA under the names Tuzucip and Trastucip via local partner Cipla.

Biosimilars Approvals

Kainos Progresses Parkinson’s Drug US Trials Amid Deal Prospects

Following ABL Bio’s sizable Parkinson’s disease drug deal with Sanofi early this year, Korean bioventure Kainos Medicine is under the spotlight as its novel PD drug candidate enters Phase II in the US.

Research & Development Clinical Trials

Solid Tumor CAR-T & AMD Gene Therapy Win EMA PRIME Designations

The first half of 2022 saw a total of seven promising treatments for unmet medical needs make it onto the European Medicines Agency’s priority medicine scheme.

Europe Drug Review

CEO Kevin Ali Marks Organon’s Progress In First Post-Spin Year

A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.

Business Strategies Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register